Hepatocellular Carcinoma Associated with Membranous Obstruction of the Inferior Vena Cava: Incidence, Characteristics, and Risk Factors and Clinical Efficacy of TACE

被引:46
作者
Gwon, Dong Il
Ko, Gi-Young [1 ]
Yoon, Hyun-Ki
Sung, Kyu-Bo
Kim, Jin Hyoung
Lee, Seung Soo
Lee, Jae Myeong
Ohm, Joon-Young
Shin, Ji Hoon
Song, Ho-Young
机构
[1] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Radiol, Seoul 138736, South Korea
关键词
BUDD-CHIARI-SYNDROME; RANDOMIZED CONTROLLED TRIAL; PORTAL-VEIN THROMBOSIS; HEPATIC PORTION; TRANSARTERIAL CHEMOEMBOLIZATION; PROGNOSTIC-FACTORS; CLIP SCORE; CIRRHOSIS; FEATURES; RECURRENCE;
D O I
10.1148/radiol.09090738
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: To analyze the characteristics associated with membranous obstruction of the inferior vena cava (MOVC) associated hepatocellular carcinoma (HCC) and to evaluate the clinical efficacy of transcatheter arterial chemoembolization ( TACE). Materials and Methods: This retrospective study was approved by an institutional review board, and informed consent was waived. Ninety-eight patients (mean age, 48.5 years +/- 12.9 [standard deviation]) with MOVC were retrospectively evaluated. The diagnosis of Budd-Chiari syndrome was confirmed with results from Doppler ultrasonography, computed tomography, magnetic resonance imaging, and/or inferior venacavography. The cumulative incidences of HCC and the patient survival period were calculated by using the Kaplan-Meier method. Factors associated with the development of HCC were evaluated by using multivariate Cox regression analysis. Results: Among 98 patients with MOVC, liver nodules were detected in 37 patients (38%), 23 of whom had HCC associated with MOVC and 14 of whom had benign nodules. The cumulative incidence of HCC at 1, 5, and 10 years was 7.3%, 13.5%, and 31.8%, respectively. Female sex was the only significant factor associated with the development of HCC (odds ratio, 6.02; P < .001). HCC was of the single nodular type and of peripheral location. Among 23 patients with HCC, 20 patients were treated with only TACE and three with liver transplantation after TACE. After TACE, 14 (61%) of the study patients had a complete response, and survival rates at 1, 2, 3, 4, and 5 years were 90%, 85%, 61%, 61%, and 46%, respectively. Conclusion: The incidence of HCC in patients with MOVC was similar to that found in other studies. TACE resulted in an effective tumor response for HCC and seemed to be effective in prolonging patient survival. Female sex was the only significant factor associated with the development of HCC. A single nodular tumor with a peripheral location appears to have a higher probability of HCC. (C) RSNA, 2010
引用
收藏
页码:617 / 626
页数:10
相关论文
共 41 条
[1]  
[Anonymous], HEPATOLOGY
[2]   Transcatheter therapy for hepatic malignancy: Standardization of terminology and reporting criteria [J].
Brown, Daniel B. ;
Gould, Jennifer E. ;
Gervais, Debra A. ;
Goldberg, S. Nahum ;
Murthy, Ravi ;
Millward, Steven F. ;
Rilling, William S. ;
Geschwind, Jean-Francois S. ;
Salem, Riad ;
Vedantham, Suresh ;
Cardella, John F. ;
Soulen, Michael C. .
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2007, 18 (12) :1469-1478
[3]   Chemoembolization for hepatocellular carcinoma [J].
Bruix, J ;
Sala, M ;
Llovet, JM .
GASTROENTEROLOGY, 2004, 127 (05) :S179-S188
[4]   Clinical management of hepatocellular carcinoma.: Conclusions of the Barcelona-2000 EASL Conference [J].
Bruix, J ;
Sherman, M ;
Llovet, JM ;
Beaugrand, M ;
Lencioni, R ;
Burroughs, AK ;
Christensen, E ;
Pagliaro, L ;
Colombo, M ;
Rodés, J .
JOURNAL OF HEPATOLOGY, 2001, 35 (03) :421-430
[5]  
CHEN MF, 1994, ARCH SURG-CHICAGO, V129, P738
[6]   HEPATIC OUTFLOW OBSTRUCTION (BUDD-CHIARI SYNDROME) - EXPERIENCE WITH 177 PATIENTS AND A REVIEW OF THE LITERATURE [J].
DILAWARI, JB ;
BAMBERY, P ;
CHAWLA, Y ;
KAUR, U ;
BHUSNURMATH, SR ;
MALHOTRA, HS ;
SOOD, GK ;
MITRA, SK ;
KHANNA, SK ;
WALIA, BS .
MEDICINE, 1994, 73 (01) :21-36
[7]   Evaluation of responses to chemoembolization in patients with unresectable hepatocellular carcinoma [J].
Ebied, OM ;
Federle, MP ;
Carr, BI ;
Pealer, KM ;
Li, W ;
Amesur, N ;
Zajko, A .
CANCER, 2003, 97 (04) :1042-1050
[8]  
ESPANA P, 1980, AM J GASTROENTEROL, V73, P28
[9]   Hepatocellular carcinoma in cirrhosis: Incidence and risk factors [J].
Fattovich, G ;
Stroffolini, T ;
Zagni, I ;
Donato, F .
GASTROENTEROLOGY, 2004, 127 (05) :S35-S50
[10]   Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis [J].
Georgiades, CS ;
Hong, K ;
D'Angelo, M ;
Geschwind, JFH .
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2005, 16 (12) :1653-1659